A new antibody to support brain health and growth in Alzheimer's patients
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease
This study is testing a new treatment that uses a special type of antibody to help protect brain cells and encourage the growth of new ones in people with Alzheimer's Disease, with the hope of improving brain function and reducing harmful proteins.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virtici, LLC NIH-funded |
| Lab location | 1 site (Seattle, UNITED STATES) |
| Project ID | NIH-10893118 on NIH RePORTER |
What this research studies
This research focuses on developing a unique bispecific antibody designed to enhance neuronal integrity and promote the growth of new neurons in individuals with Alzheimer's Disease (AD). The approach involves targeting specific proteins in the brain that are linked to the progression of AD, aiming to reduce harmful protein accumulation and improve brain function. By utilizing advanced antibody technology, the research seeks to create a treatment that could potentially reverse some of the damaging effects of AD. Patients may be involved in trials to assess the safety and effectiveness of this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's Disease or those exhibiting early signs of cognitive decline.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's Disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that not only alleviates symptoms of Alzheimer's Disease but also promotes brain health and regeneration.
How similar studies have performed: While there have been various approaches to treating Alzheimer's, this specific bispecific antibody strategy is novel and has not been extensively tested in previous studies.
Where this research is happening
Seattle, UNITED STATES
- Virtici, LLC — Seattle, United States (Active)
Researchers
- Principal investigator: Fanger, Neil a — Virtici, LLC
- Study coordinator: Fanger, Neil a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.